Cardiometabolic Health in Women: Risks, Conditions, and Evidence-Based Treatment

What Cardiometabolic Health Means

Cardiometabolic health is not one diagnosis. It is the combined state of the cardiovascular, kidney, and metabolic systems. High blood pressure can damage the heart and kidneys. Chronic kidney disease can increase cardiovascular risk. Insulin resistance, diabetes, abnormal lipids, smoking, sleep apnea, and excess visceral fat can amplify the same pathway.

The 2026 AHA/ACC/ADA/ASN guideline formalizes this overlap as cardiovascular-kidney-metabolic syndrome and organizes prevention around both disease stage and absolute risk. It also emphasizes that treatment should address the connected system rather than chase one laboratory value at a time. 1

For women, a complete assessment includes the usual risk factors and a reproductive history. Pregnancy can act as a physiologic stress test. PCOS can reveal metabolic susceptibility in early adulthood. Menopause can coincide with adverse changes in lipids, body composition, and vascular health. None of these events proves that cardiovascular disease will occur, but each can change how closely risk factors should be followed.

A Practical Cardiometabolic Assessment for Women

A useful baseline assessment answers five questions:

1. Is disease already present? Ask about prior heart attack, stroke, peripheral artery disease, heart failure, chronic kidney disease, hypertension, diabetes, and fatty liver disease.
2. What is the current risk-factor burden? Measure blood pressure correctly and review a lipid panel, glucose status, tobacco exposure, sleep, activity, nutrition, family history, and medications.
3. Does reproductive history add risk information? Record PCOS, infertility treatment, gestational diabetes, hypertensive disorders of pregnancy, preterm delivery, pregnancy loss, and age and reason for menopause.
4. Could symptoms indicate a different condition? Fatigue and weight change can also reflect anemia, thyroid disease, sleep apnea, depression, medication effects, or inadequate energy intake.
5. Could treatment affect pregnancy or fertility plans? This question changes the choice and timing of lipid, blood-pressure, diabetes, and weight-management medicines.

The 2019 ACC/AHA primary prevention guideline identifies pregnancy-associated conditions such as preeclampsia and premature menopause before age 40 as risk-enhancing factors during clinician-patient risk discussions. It does not say that every affected woman automatically needs a statin. The decision still depends on age, lipid levels, overall risk, preferences, and sometimes additional testing. 2

Tests that often matter

The exact panel should follow the clinical question, but the usual building blocks are:

• repeated, properly obtained blood-pressure measurements
• fasting or nonfasting lipid profile
• A1C, fasting glucose, or an oral glucose tolerance test when indicated
• creatinine with estimated glomerular filtration rate
• urine albumin-to-creatinine ratio in diabetes, hypertension, or suspected kidney disease
• liver enzymes when metabolic liver disease or medication monitoring is relevant
• pregnancy testing before a treatment that should not be used during pregnancy

Waist circumference can add information about central adiposity, but it is not a diagnosis by itself. Likewise, fasting insulin is not a universal screening test for "insulin resistance." Glucose measurements, A1C, and in selected settings an oral glucose tolerance test have clearer diagnostic roles.

Pregnancy History Is Long-Term Health History

Gestational diabetes, hypertensive disorders of pregnancy, preterm delivery, placental abruption, and delivery of a small-for-gestational-age infant are associated with later cardiovascular risk. The American Heart Association describes these adverse pregnancy outcomes as opportunities for earlier prevention, not as deterministic forecasts. 3

That distinction matters. A history of preeclampsia should prompt careful follow-up of blood pressure, lipids, glucose, weight trajectory, smoking, and physical activity. It does not establish that a current symptom is cardiac, and it does not replace ordinary diagnostic testing.

Women may lose continuity of care after delivery because obstetric care ends before primary-care follow-up is established. A practical medical record should carry pregnancy complications forward into the permanent problem or risk history so they are still visible years later.

PCOS and Metabolic Risk

Polycystic ovary syndrome is a reproductive and metabolic condition, not simply a fertility or cosmetic diagnosis. The 2023 International Evidence-based PCOS Guideline recognizes higher risks of impaired glucose tolerance, type 2 diabetes, sleep apnea, and adverse pregnancy outcomes. It recommends assessing glycemic status at diagnosis in adults and adolescents with PCOS, regardless of BMI, and reassessing every 1 to 3 years according to other risk factors. The 75-g oral glucose tolerance test is the most accurate glycemic test in PCOS, although fasting glucose or A1C may be used when an OGTT cannot be performed. 4

PCOS does not mean that every woman has insulin resistance, nor does it justify a fixed supplement or medication stack. Management depends on the goal:

• lifestyle support and prevention of excess weight gain for long-term health
• cycle regulation or endometrial protection when periods are infrequent
• treatment of hirsutism or acne when desired
• fertility treatment when pregnancy is the goal
• metformin in selected metabolic or reproductive circumstances
• treatment of hypertension, dyslipidemia, diabetes, sleep apnea, or depression when present

The guideline specifically cautions against weight stigma and does not endorse a single "PCOS diet." Sustainable dietary patterns and activity plans can be adapted to culture, symptoms, access, and preferences.

Gestational Diabetes: Screening, Treatment, and Follow-Up

The USPSTF recommends screening asymptomatic pregnant people for gestational diabetes at 24 weeks of gestation or later. It recognizes both the common US two-step strategy and the one-step oral glucose tolerance test. For asymptomatic people before 24 weeks, the USPSTF found the evidence insufficient to determine the balance of benefits and harms of routine gestational-diabetes screening. That is different from testing early for previously unrecognized overt diabetes when risk or clinical findings warrant it. 5

Once gestational diabetes is diagnosed, nutrition, physical activity, glucose monitoring, and pregnancy-specific targets form the initial plan. The ADA's 2026 pregnancy standards state that insulin is the preferred medication when pharmacologic treatment is needed. Metformin and glyburide should not be first-line agents because they cross the placenta and may not achieve treatment goals in every patient. 6

Care does not end at delivery. The ADA recommends a 75-g oral glucose tolerance test at 4 to 12 weeks postpartum because A1C can be misleading after pregnancy-related blood loss and altered red-cell turnover. If the postpartum test is normal, lifelong screening every 1 to 3 years remains appropriate. 6

The long-term risk is modifiable. In the Diabetes Prevention Program, intensive lifestyle intervention reduced diabetes incidence by 58% and metformin by 31% during the original trial compared with placebo. A 21-year analysis confirms persistent, although attenuated, prevention effects and shows why structured follow-up matters more than a one-time warning. 7

Menopause and Cardiovascular Risk

Menopause does not suddenly create cardiovascular disease. Aging and the menopause transition overlap, and both influence risk. Longitudinal evidence reviewed by the American Heart Association shows that the transition is associated with adverse changes in body composition, lipids and lipoproteins, and vascular health. Midlife is therefore a useful time to reassess established risk factors. 8

Useful midlife questions include:

• Has blood pressure risen across repeated measurements?
• Have LDL cholesterol or triglycerides changed?
• Has glucose status changed?
• Has activity fallen because of symptoms, caregiving, pain, or sleep disruption?
• Is new central weight gain part of a broader metabolic pattern?
• Was menopause premature or caused by surgery or treatment?

Hormone therapy is not a cardiovascular prevention drug

Menopausal hormone therapy is the most effective treatment for vasomotor symptoms and can prevent bone loss, but its risks and benefits depend on formulation, dose, route, timing, duration, and the individual's health history. The 2022 North American Menopause Society position statement says the benefit-risk ratio is generally favorable for symptomatic women younger than 60 or within 10 years of menopause onset who lack contraindications. The ratio is less favorable when therapy begins later because absolute risks of coronary disease, stroke, venous thromboembolism, and dementia are higher. 9

Hormone therapy should not be started solely to prevent cardiovascular disease. Conversely, a risk factor such as well-controlled hypertension does not answer the hormone-therapy question by itself. The symptom target, route, uterine status, clotting and cancer history, age, and time since menopause all matter.

Cardiometabolic Health in Female Athletes

High exercise volume is not automatically protective if energy intake is insufficient. The 2023 International Olympic Committee consensus defines relative energy deficiency in sport, or REDs, as impaired physiologic or psychological functioning caused by problematic low energy availability. Possible effects include altered energy metabolism, reproductive function, bone and musculoskeletal health, immunity, cardiovascular health, and performance. 10

Warning patterns include menstrual disruption, recurrent bone stress injuries, declining performance, frequent illness, persistent fatigue, mood change, or restrictive eating. No single calorie threshold, hormone result, or questionnaire proves REDs. The IOC REDs Clinical Assessment Tool, version 2, uses screening followed by clinical severity and risk assessment; it is not meant to be used in isolation. 10

Treatment centers on correcting the mismatch between intake, exercise expenditure, and recovery. That may require nutrition support, changes in training, treatment of an eating disorder, and management of bone or reproductive complications. Automatically prescribing an oral contraceptive can create withdrawal bleeding without demonstrating restoration of adequate energy availability.

Evidence-Based Treatment Priorities

1. Treat measured risk, not a gender stereotype

Blood pressure, LDL cholesterol, glucose, kidney function, smoking, and established disease remain major drivers of treatment. Reproductive factors add context and can justify closer assessment, but they do not support a universal female-specific drug protocol.

For adults with diabetes, the ADA's 2026 cardiovascular standards recommend a multifactorial approach. Depending on the patient, that can include blood-pressure treatment, lipid lowering, smoking cessation, kidney protection, and a glucose-lowering medicine with demonstrated cardiovascular or heart-failure benefit. Medication selection follows the disease present: ASCVD, heart failure, chronic kidney disease, obesity, or glycemic need. 11

2. Use lifestyle treatment as specific therapy

"Eat better and exercise" is not a usable prescription. Effective plans define the next behavior: replace sugar-sweetened drinks, add a repeatable high-fiber breakfast, walk after a meal, schedule resistance training, address food insecurity, stop smoking, or treat sleep apnea. The Diabetes Prevention Program demonstrates that an intensive, structured intervention can prevent diabetes; it does not show that brief generic advice produces the same result. 7

3. Use weight-loss medications for an indicated condition

In STEP 1, 1,961 adults with overweight or obesity and without diabetes were randomized to semaglutide 2.4 mg or placebo, both with lifestyle intervention. Mean weight change at 68 weeks was -14.9% with semaglutide and -2.4% with placebo. The trial supports substantial average efficacy, not a guaranteed result for an individual. 12

In SURMOUNT-1, 2,539 adults with obesity or overweight plus a weight-related complication and without diabetes received tirzepatide or placebo. Mean weight reduction at 72 weeks reached 20.9% with the 15-mg dose versus 3.1% with placebo. Gastrointestinal adverse events were common, and trial-level averages do not decide whether the medicine is appropriate for a particular patient. 13

Neither trial was a PCOS-specific treatment trial, and neither justifies using these medicines during pregnancy. Preconception planning should include enough time to discontinue weight-loss medication and establish an alternative metabolic plan according to the current product labeling and diabetes guidance.

4. Match diabetes medication to cardiovascular and kidney disease

For type 2 diabetes with established ASCVD, chronic kidney disease, or heart failure, drug choice should consider outcome evidence rather than A1C alone. Depending on the condition, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit may be indicated as part of comprehensive risk reduction. Sex alone does not determine the agent, and pregnancy changes the medication framework substantially. 11

5. Review every medication when pregnancy is possible or planned

The old blanket statement that statins are "strictly contraindicated" in every pregnancy is outdated. In 2021, the FDA removed that class-wide strongest warning because a small group at very high cardiovascular risk may benefit from individualized decisions. The FDA still advises that most pregnant patients stop statins. 14

ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and weight-loss medications also require preconception review. Do not stop a necessary medicine based only on a web article; the safer process is a medication-by-medication plan with the prescriber before conception when possible.

When Symptoms Need Prompt Evaluation

Cardiometabolic prevention is usually longitudinal, but some symptoms should not wait for a routine risk visit. Seek urgent evaluation for chest pressure or pain, severe shortness of breath, fainting, new one-sided weakness, facial droop, difficulty speaking, or a sudden severe headache. During pregnancy or postpartum, severe headache, vision change, chest pain, shortness of breath, marked swelling, or very high blood pressure also requires prompt assessment.

Symptoms may be less dramatic than a stereotyped crushing chest pain. The important rule is not that women always present "atypically." It is that clinicians and patients should take possible cardiac or neurologic symptoms seriously and use the same timely diagnostic standards.

A Life-Stage Follow-Up Plan

A practical plan can be organized around transitions:

• Reproductive years: document PCOS and pregnancy intentions; screen conventional risk factors according to age and clinical history.
• During pregnancy: identify preexisting diabetes and hypertension, screen for gestational diabetes at the recommended time, and use pregnancy-specific treatment targets.
• After an adverse pregnancy outcome: complete postpartum testing, transfer the history to primary care, and build a long-term prevention plan.
• Perimenopause and menopause: repeat blood pressure, lipid, and glucose assessment; address sleep, activity, symptoms, and body-composition change.
• Later life: treat absolute cardiovascular, kidney, and fracture risk while accounting for function, medication burden, and patient goals.

This approach is more accurate than labeling all women as high risk or assuming that normal weight means low risk. It also creates an answer that can be updated: what changed, what was measured, what condition is being treated, and when the next assessment is due.